Olema Pharmaceuticals, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $7.22
- 52-Week Range
- $6.24 – $36.26
- Market Cap
- $618.50M
- P/E (TTM)
- —
- EPS (TTM)
- -2.40
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.68
- PEG Ratio
- —
- Return on Equity
- -69.77%
- Return on Assets
- -39.82%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 6.12
- Debt/Equity
- 0.01
- Total Debt
- $3.36M
- Free Cash Flow
- $-95.10M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $208.09M
Market Snapshot
About
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for estrogen receptor-positive breast cancer. The company focuses on endocrine therapies designed to overcome resistance mechanisms in HR+ breast cancer. Olema's lead candidate is palazestrant, a complete estrogen receptor antagonist in clinical trials.